Histone deacetylase inhibitors and retinoic acids inhibit growth of human neuroblastoma in vitro. Academic Article uri icon

Overview

abstract

  • BACKGROUND: Neuroblastoma is a common childhood cancer with a poor overall prognosis. Retinoic acids (RAs) have been studied as a potential therapy, showing promise in recurrent disease. The histone deacetylase inhibitor (HDACI) M-carboxycinnamic acid bishydroxamide (CBHA) is another potential therapy, which we recently described. Combinations of RAs and HDACIs currently under investigation display synergy in certain neoplasms. In this study, we evaluate the effect of combinations of RAs and HDACIs on human neuroblastoma cells. PROCEDURE: Established cell lines were cultured in increasing concentrations of HDACIs, RAs, and combinations thereof. Following exposure, viable cell number was quantified by trypan blue dye exclusion on a hemacytometer. Cell cycle analysis was performed by propidium iodide staining and FACS. RESULTS: All assayed HDACIs and RAs decreased viable cell number. Lower concentrations of each agent were effective when the two were combined. The primary reason for decreased cell number appears to be apoptosis following HDACI exposure and G1 arrest following RA exposure. Both effects are seen with cotreatment. Caspase inhibition abrogates the apoptotic response. CONCLUSIONS: CBHA causes apoptosis of human neuroblastoma in vitro, an effect that can add to the effects of RA. HDACIs and RAs inhibit neuroblastoma in significantly lower concentrations when used together than when used individually. Combination therapy may improve the ultimate efficacy while reducing the side effects of these agents in clinical use.

publication date

  • December 1, 2000

Research

keywords

  • Antineoplastic Combined Chemotherapy Protocols
  • Cinnamates
  • Histone Deacetylase Inhibitors
  • Neuroblastoma
  • Tretinoin

Identity

Scopus Document Identifier

  • 0033646839

Digital Object Identifier (DOI)

  • 10.1002/1096-911x(20001201)35:6<577::aid-mpo18>3.0.co;2-3

PubMed ID

  • 11107121

Additional Document Info

volume

  • 35

issue

  • 6